(Q43265473)

English

Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation

scientific article published on 6 October 2009

In more languages
default for all languages
No label defined

No description defined

Statements

Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation (English)
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit